NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (NRXP) is a clinical-stage biopharmaceutical company that traces its public-market origins to Big Rock Partners Acquisition Corp. (BRPA), a blank-check company sponsored by Big Rock Partners LLC that completed its SPAC IPO in 2018. Operating in the healthcare and pharmaceutical sector with a focus on treatments for severe psychiatric and life-threatening conditions — including NRX-101 for bipolar depression — the company underwent a name change from Big Rock Partners Acquisition Corp. to NRX Pharmaceuticals ahead of completing its business combination with NeuroRx, Inc. in 2021. The 10-Q filed in August 2020 reflects the entity during its pre-merger transitional period as a publicly listed shell. Shares trade on Nasdaq under the ticker NRXP. For comprehensive filing history, deal terms, pipeline data, and SPAC structure details on NRX Pharmaceuticals and thousands of other transactions, sign up for full access at SpacDesk.